Atara Biotherapeutics’ Post

Happening tomorrow! Join CEO Pascal Touchon for a fireside chat at Stifel Financial Corp.’s Virtual Cell Therapy Forum. The presentation will be webcast live at: https://bit.ly/3RYyO5M, with a replay available shortly thereafter.

Happening tomorrow! Join CEO Pascal Touchon and CSO Cokey Nguyen for a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The presentation will be webcast live at: https://bit.ly/3VBZCdY, with a replay available shortly thereafter.

CSO Cokey Nguyen will be joining a panel with fellow cell therapy experts this Thursday at #BIO2024 in San Diego on June 6. Join us to learn about the latest developments and future trends in #allogeneic cell therapies, which are poised to usher in a new wave of innovation.

We are pleased to announce that Atara will be presenting new #SLE and #MS preclinical data today for our investigational CD19 #allogeneic #CART therapy, ATA3219, at the International Society for Cell & Gene Therapy 2024 Annual Meeting in Vancouver, Canada. Read all the details here: https://bit.ly/3yzWrKO

Today Atara announced that it submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. This represents the first-ever #allogeneic #Tcell therapy BLA submission to the FDA, and if approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read more about this significant milestone for Atara: https://bit.ly/4dL7elE

Hear from our CSO, Cokey Nguyen, on how Atara is leveraging its #EBV T cells for our promising #allogeneic #CART platform in oncology and autoimmune diseases. Read the entire article starting on page 44 here: https://lnkd.in/dv3Bi45P

Today we announced our first quarter 2024 financial results and operational progress. The latest news is available here: https://bit.ly/4adw4rd #celltherapy #allogeneic #CART $ATRA

Tune in today at 11:30am PT as CEO Pascal Touchon presents a company overview at the Aegis Capital Corp. Virtual Conference. Register here: https://bit.ly/3JQGOkv

ICYMI, CSO Cokey Nguyen joined a Cell & Gene Live session to discuss the current and future trends of #allogeneic #Tcell therapies for oncology, and the latest manufacturing strategies and approaches to help bring these off-the-shelf treatments to patients.